5-IAI

Use and effects

The human dosage of 5-IAI has been described as 100 to 200mg and its duration of action as 2 to 4hours. Human anecdotal reports suggest that 5-IAI is entactogenic and that it increases sociability and trust. On the other hand, it is reported that 5-IAI produces very little euphoria and is far less stimulating than MDMA and other amphetamines. Relatedly, 2-aminoindanes like 5-IAI never gained widespread popularity as recreational drugs, probably due to their relative lack of euphoria.

Interactions

Pharmacology

Pharmacodynamics

Similarly to MDMA, 5-IAI acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). Its values for induction of monoamine release have not been reported. In any case, its relative potency for monoamine release is serotonin dopamine norepinephrine. In addition, 5-IAI's affinity (Ki) values for the monoamine transporters are 879nM for the serotonin transporter (SERT), 311nM for the norepinephrine transporter (NET), and 992nM for the dopamine transporter (DAT), whereas its values in terms of functional inhibition have been reported to be 241nM or 2,500nM at the SERT, 612nM or 760nM at the NET, and 992nM or 2,300nM at the DAT in two different respective studies.

In addition to its interactions with the monoamine transporters, 5-IAI shows high affinity for the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors, as well as affinity for the α2A-, α2B-, and α2C-adrenergic receptors. The high affinity for the serotonin receptors is in contrast to MDAI.

5-IAI and MDAI fully substitute for MDMA in drug discrimination tests in rodents. This suggests that they produce MDMA-like subjective and entactogenic effects in rodents.

Unlike related 2-aminoindane derivatives like MDAI and MMAI, 5-IAI causes some serotonergic neurotoxicity in rats (15% or less reduction of serotonergic markers), but is less neurotoxic than its corresponding amphetamine homologue para-iodoamphetamine (pIA) and the doses employed have been described as "extremely high". In any case, regular high-dose 5-IAI has been found to produce cognitive and memory deficits in rodents.

History

5-IAI was first described in the scientific literature by David E. Nichols and colleagues at Purdue University in 1991. It was encountered as a novel designer drug online in 2010 and in the United Kingdom in 2011.

Society and culture

Legal status

Finland

Scheduled in the "government decree on psychoactive substances banned from the consumer market".

Sweden

Sweden's public health agency suggested classifying 5-IAI as a hazardous substance, on September 25, 2019.

References

References

1. Anvisa. (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. (March 2013). "5-Iodo-2-aminoindan (5-IAI): chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects". Toxicol Lett.
3. (July 1991). "[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues". European Journal of Pharmacology.
4. (January 1991). "5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine". Pharmacology Biochemistry and Behavior.
5. (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol.
6. "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista | 1130/2014 | Lainsäädäntö | Finlex".
7. (25 September 2019). "Tretton ämnen föreslås klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten.